Company Overview
Foghorn Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery and development of medicines that target genetically determined dependencies within the chromatin regulatory system in the United States. The company utilizes its proprietary Gene Traffic Control platform to identify and develop therapeutics, positioning itself within the broader Healthcare sector and the specialized Biotechnology industry. Foghorn Therapeutics Inc. currently maintains a market capitalization of $289.39M and employs a workforce of 106 individuals to support its research and development initiatives. The annual revenue generated in the trailing twelve months stands at $30.91M, indicating a mid-stage enterprise that has achieved commercialization milestones but remains in a phase of intensive capital expenditure to advance its pipeline. These valuation and revenue figures suggest the company occupies a position where significant growth potential exists, yet the market cap reflects the high risk and speculative nature often associated with clinical-stage biotechnology firms that have not yet established sustained profitability.
Financial Health
In the trailing twelve months, Foghorn Therapeutics Inc. reported revenue of $30.91M, net income of -$74,283,000, and EBITDA of -$78,775,000, highlighting a substantial divergence between top-line sales and bottom-line profitability. The significant gap between revenue and net income reveals a cost structure characterized by heavy operating expenses typical of biotechnology companies in the clinical development phase, where research, development, and regulatory costs far exceed current sales revenues. The company reported free cash flow of -$35,229,876, which indicates a continuous consumption of cash resources required to fund ongoing operations and clinical trials without generating positive cash returns at this stage. The gross margin stands at -176.5%, the operating margin at -211.9%, and the profit margin at -240.3%, all of which are negative figures reflecting the pre-revenue or low-revenue operational dynamics where fixed costs exceed gross sales. Regarding balance sheet leverage, the company holds $158.89M in cash against $41.27M in debt, though the debt-to-equity ratio is listed as N/A, suggesting the equity base may be negative or insufficient to calculate a traditional leverage multiple. The current ratio of 2.73 indicates that the company possesses $2.73 in current assets for every $1 of current liabilities, demonstrating a robust short-term liquidity position capable of meeting its immediate financial obligations. Return on Equity is listed as N/A due to the negative equity position common in loss-making biotechs, while the Return on Assets is -21.3%, revealing that the asset base is currently generating negative returns relative to its total book value.
Valuation Assessment
The trailing P/E ratio for Foghorn Therapeutics Inc. is N/A due to negative earnings, while the forward P/E is -5.41, a metric that implies the market is pricing in expectations of future earnings recovery rather than current profitability. The price-to-book ratio is -2.57, indicating that the market values the company at a negative multiple of its book value, which typically occurs when shareholder equity is negative due to accumulated losses. The price-to-sales ratio stands at 9.36, suggesting that investors are willing to pay a premium of 9.36 times for every dollar of revenue, a valuation metric often used for high-growth biotechnology firms that lack historical profitability. The enterprise value to EBITDA is -2.18, an alternative valuation metric that further underscores the company's current lack of earnings power and reliance on cash reserves to fund operations. The stock has traded between a 52-week high of $6.95 and a 52-week low of $2.94, meaning the current trading price fluctuates within a range that represents a volatility of over 136% from the low to the high. With a beta of 3.12, the stock exhibits significant price volatility, moving more than three times as much as the broader market, which reflects the high risk profile associated with small-cap biotechnology equities.
Growth & Income
Foghorn Therapeutics Inc. has achieved a revenue growth rate of 223.8% year-over-year, while the earnings growth rate is N/A, indicating that top-line expansion is occurring without corresponding immediate earnings improvement. This disparity implies that the company is in a scaling phase where revenue increases are being absorbed by rising operational costs and clinical trial expenditures rather than translating into net income yet. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests all available capital and operational cash flow back into its research and development pipeline rather than distributing income to shareholders. Consequently, the overall growth and income profile is defined entirely by capital appreciation potential driven by clinical milestones and revenue expansion, rather than income generation or dividend yield. The absence of a dividend payout aligns with the company's lifecycle stage, where preserving cash is critical for advancing its proprietary Gene Traffic Control platform and bringing potential therapies to market.